Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could potentially expand access to millions of patients and give the Danish company a much-needed fillip in the red-hot market. The first GLP-1 pill specifically for ​obesity, also branded as Wegovy, is a 25-mg oral formulation of semaglutide, the active ingredient in the blockbuster injectable version.

Going on a tight spending plan doesn't mean you need to forfeit quality encounters or wonderful objections. There are a lot of fantastic

Consumer choices about what to eat and how much of it can affect how much water farmers need to use.